Fluvoxamine

Fluvoxamine

Fluvoxamine is an SSRI (selective serotonin reuptake inhibitor) that's mostly prescribed for OCD, but is also widely used for social anxiety, panic disorder, and depression. It's the SSRI of choice when intrusive, repetitive, or obsessive thinking is the dominant problem rather than low mood, and one of the older drugs in the class, first approved in the 1980s.
What sets fluvoxamine apart from the rest of the SSRI family is that it's a strong agonist at the sigma-1 receptor, a chaperone protein on the endoplasmic reticulum that's involved in cellular stress responses, neuroprotection, and inflammation control. This is the basis for its growing reputation outside psychiatry: it's been studied for cognitive recovery in depression, neuroprotection in stroke and neurodegeneration, and most prominently as an outpatient COVID-19 treatment, where multiple trials suggested it lowered hospitalisation risk. Most people taking fluvoxamine are doing so for OCD or anxiety, but the sigma-1 angle is why it keeps showing up in unusual places.
It's a prescription drug. Onset takes weeks (usually 4-12 for full effect on OCD), and stopping it abruptly causes a real withdrawal syndrome. This isn't something to start or stop on a whim.

Deep-dive

Fluvoxamine works through two distinct mechanisms that probably both matter clinically.
Serotonin reuptake inhibition. Like every SSRI, fluvoxamine blocks the serotonin transporter (SERT), increasing synaptic serotonin and over weeks driving downstream changes in receptor density, BDNF expression, and circuit-level signalling that underlie its antidepressant and anti-obsessive effects. At therapeutic doses (50-300 mg/day), SSRIs occupy roughly 80% of SERT, and fluvoxamine sits in the same general potency range as sertraline and citalopram, with a half-life of about 16 hours.
Sigma-1 receptor agonism. Of all SSRIs, fluvoxamine has the highest affinity for the sigma-1 receptor, with low-nanomolar potency. Sigma-1 is a chaperone protein on the endoplasmic reticulum that regulates calcium signalling between the ER and mitochondria, modulates NMDA and ion channel function, and dampens ER stress and the unfolded protein response. Activating it induces sigma-1 expression itself, prevents neuronal cell death from ER stress, and reduces infarct size in animal models of stroke. This is the mechanism people point to when they talk about fluvoxamine's neuroprotective and anti-inflammatory effects, and it's mostly absent from the other SSRIs.
OCD. This is where fluvoxamine has the strongest evidence. Placebo-controlled trials going back to the late 1980s established its efficacy, and a 12-week trial of the controlled-release formulation in 253 adults found significant reductions in Y-BOCS score with response starting from week 2. Comparative trials suggest fluvoxamine is roughly equivalent to clomipramine for OCD but better tolerated. A recent overview of systematic reviews confirmed superiority over placebo for OCD across 16 RCTs and 1,745 patients. Fluvoxamine isn't necessarily more effective than other SSRIs for OCD on average, but it tends to be the first one psychiatrists reach for when OCD is the primary diagnosis.
Social anxiety disorder. A 12-week placebo-controlled trial at a mean dose of 202 mg/day produced significantly higher response rates than placebo on the Liebowitz Social Anxiety Scale. The extended-release formulation showed similar results in 279 patients, with effects emerging at week 4 and continuing through a 12-24 week extension phase. High-quality systematic reviews consistently rank fluvoxamine as effective for SAD, though dropout rates from side effects are higher than for some alternatives.
Panic disorder. Mixed results. Earlier trials showed fluvoxamine outperformed both placebo and imipramine for reducing panic attack frequency, but pooled analyses haven't always reached statistical significance. It works for panic, but it isn't usually the first SSRI chosen for it.
Depression. Approved for depression in much of Europe and the UK but not in the US, where it's only labelled for OCD. Efficacy is comparable to other SSRIs. The sigma-1 angle is interesting here: a review on cognition and depression argued that fluvoxamine's sigma-1 agonism may help reverse the cognitive impairment that other antidepressants can worsen, by promoting neurogenesis and adaptive neural plasticity in regions affected by depression-induced atrophy.
COVID-19. This is where fluvoxamine got its second life. The TOGETHER trial, a randomised platform trial in 1,497 high-risk symptomatic outpatients in Brazil, found that 100 mg twice daily for 10 days reduced the composite endpoint of emergency observation or hospitalisation. A meta-analysis of three randomised trials including STOP COVID 1, STOP COVID 2, and TOGETHER found a 31% reduction in clinical deterioration or hospitalisation. The ACTIV-6 trial using a lower dose (50 mg twice daily) in a heavily vaccinated population didn't find a benefit on time to recovery. The proposed mechanism is sigma-1 driven: dampening of ER-stress driven inflammation (IRE1, ATF6, PERK pathways), reduced platelet aggregation, decreased mast cell degranulation, and possibly direct interference with viral entry and trafficking. Regulatory bodies haven't endorsed it for COVID, but it remains one of the few repurposed drugs with positive RCT data.
Cognition and neuroprotection. Beyond depression, fluvoxamine has been investigated for cognitive recovery in schizophrenia and Alzheimer's, where the sigma-1 mechanism plausibly applies. A ketamine-induced rat model of schizophrenia showed fluvoxamine improved learning, cognitive flexibility, and social behaviour while reducing ER stress markers and inflammation, with all effects abolished by a sigma-1 antagonist. Human cognitive evidence is much thinner. The mechanism is suggestive, the clinical proof in healthy or non-depressed people isn't there.
Women. Fluvoxamine pharmacokinetics differ between sexes. Women develop higher serum concentrations than men at the same 100 mg/day dose, with the difference disappearing at 200 mg/day, suggesting saturable enzyme metabolism. The pediatric labelling reflects this too: therapeutic effect in female children may be achieved at lower doses than in males. In practice, women often need less than men for the same response. Efficacy in OCD, SAD, and panic appears similar between sexes across trials. The discontinuation syndrome and side effect profiles are also similar, though women tend to report more intense sexual side effects when they occur, even though men report them more frequently.
Pregnancy and breastfeeding. Observational data hasn't established increased risk of major congenital malformations from fluvoxamine in pregnancy, but third-trimester SSRI exposure carries a small increased risk of neonatal pulmonary hypertension and post-natal adaptation syndrome (jitteriness, feeding difficulty). For breastfeeding, transfer into milk is low, with relative infant doses below 1%, and most case reports show undetectable infant serum levels. The decision is individualised, but discontinuing during pregnancy carries its own real relapse risk, especially in OCD where stable treatment matters.
Older adults. Pharmacokinetics are largely unchanged with age, but liver impairment reduces clearance by about 30%, so start lower and titrate slowly. Caution with the bleeding risk noted below since older adults are more often on antiplatelets or anticoagulants.

Dosage:

  • Standard adult dose: 50-300 mg/day. Start at 50 mg in the evening for the first week, then increase by 50 mg every 4-7 days based on tolerability. Most people land at 100-200 mg/day for OCD or SAD, sometimes higher (up to 300 mg) for treatment-resistant OCD
  • Splitting doses: Once daily dosing at bedtime works for doses up to about 100-150 mg. Above 150 mg, split into a smaller morning and larger bedtime dose to reduce GI side effects. Controlled-release (CR) formulations stay once daily across the range
  • Women may need less. Female patients tend to reach higher serum concentrations than men at the same dose, particularly at 100 mg/day. Start at 50 mg and reassess before pushing higher
  • Older adults and liver impairment: start at 25-50 mg, titrate slowly. Clearance is reduced by ~30% with hepatic dysfunction
  • Time to effect: 2-4 weeks for early signs of improvement, 8-12 weeks for full effect on OCD. Don't judge response before week 6
  • Discontinuation: Never stop abruptly. Fluvoxamine has a 16-hour half-life, which puts it in the high-risk category for discontinuation syndrome. Standard guidance is to taper by 25-50 mg every 2-4 weeks. Slower hyperbolic tapering (proportional rather than linear reductions) is increasingly recommended to minimise withdrawal, especially after long-term use. If symptoms emerge, slow down or briefly hold the previous dose
  • Caffeine: This deserves its own line. Fluvoxamine is the most potent CYP1A2 inhibitor in the SSRI class, and caffeine clearance drops by ~80% on fluvoxamine, with caffeine half-life extending from 5 hours to 31 hours. Cut your caffeine intake by 50-75%, or you'll experience effective caffeine intoxication: anxiety, insomnia, palpitations. People often don't connect the symptoms to coffee
  • Stacks and interactions: Strong CYP1A2 inhibition also affects melatonin (large bioavailability increase, more grogginess), theophylline, clozapine, olanzapine, tizanidine, ramelteon, agomelatine, and others. CYP3A4 is also moderately inhibited, affecting some benzodiazepines and statins. Always check for interactions before combining
  • Hard contraindications: MAOIs (need a 14-day washout in either direction), pimozide, thioridazine, tizanidine, ramelteon, alosetron. Combining with serotonergic drugs (other SSRIs/SNRIs, MDMA, tramadol, triptans, dextromethorphan, St John's wort) raises serotonin syndrome risk

Here's what you can expect:

The first 1-2 weeks are usually the worst. Nausea, headache, sleep disturbance, increased anxiety, and emotional flatness are common as your system adjusts. Most of this fades by week 3-4, but starting low and titrating slowly makes a meaningful difference. If you start at 100 mg straight off, you'll often feel awful and quit before it has a chance to work.
Real therapeutic benefit takes time. Anxiety and panic symptoms often improve first, by week 2-4. OCD symptoms take longer, often 8-12 weeks for full effect, and improvement tends to be gradual rather than sudden. Don't expect to feel "better" in the first month, expect to feel less reactive, less stuck in the loop, less consumed by the obsession.
Emotional blunting is a real and often underdiscussed effect. Things that used to feel intense, both negative and positive, get muted. For someone with severe OCD or panic, this is often welcome at first. Long-term, it's the most common reason people choose to come off.
Sexual side effects affect a meaningful minority. Across SSRIs, fluvoxamine sits at the lower-frequency end of the class (less than paroxetine, fluoxetine, citalopram, sertraline) but it's not zero. Around 8% of men report abnormal ejaculation, 2% report impotence, and roughly 2% of both sexes report decreased libido or anorgasmia in clinical trial reporting. Real-world rates are higher when patients are asked directly. Notably, fluvoxamine doesn't meaningfully delay ejaculation the way paroxetine and sertraline do, which is one reason it's a poor choice for premature ejaculation but a reasonable choice for someone who wants to minimise this side effect class.
By month 2-3 most people have reached a stable steady state where the OCD or anxiety burden is meaningfully lower and the side effects have settled to whatever the long-term baseline is going to be.

Side effects & risks:

  • Nausea and GI symptoms are the most common, especially early on. Splitting doses and taking with food helps. Usually settles within 2-4 weeks
  • Sleep disruption. Fluvoxamine can cause insomnia or vivid dreams in some, sedation in others. Bedtime dosing usually helps if it's sedating, morning dosing if it's activating
  • Headache and dizziness are common in the first weeks
  • Sexual dysfunction. Lower frequency than most other SSRIs but still affects a meaningful percentage. Decreased libido, delayed orgasm, anorgasmia, erectile difficulties. Often persists for the duration of treatment
  • Emotional blunting. Reduced emotional reactivity in both directions. Hard to quantify in trials but very common in real-world reports
  • Sweating (antidepressant-induced excessive sweating, ADIES). Dose-related
  • Increased bleeding risk. SSRIs reduce platelet serotonin uptake, which mildly impairs platelet function. Clinically relevant when combined with NSAIDs, aspirin, anticoagulants, or in the perioperative period
  • Hyponatraemia (low sodium). Uncommon but more frequent in older adults, can be serious. Risk factors include diuretic use, older age, female sex, low body weight
  • QT prolongation. Less concerning than citalopram but still worth knowing about if you have cardiac risk factors or are on other QT-prolonging drugs
  • Activation and increased anxiety in the first 2 weeks. Counterintuitive but common. Usually transient. Starting at a low dose mitigates this
  • Suicidal ideation in young people. SSRIs carry a black-box warning for increased suicidal thoughts in patients under 25 during the first weeks of treatment. Risk is highest at initiation and dose changes, and is partially counterbalanced by reduced risk from treating the underlying disorder. Worth honest discussion if relevant
  • Serotonin syndrome. A potentially life-threatening reaction from excessive serotonergic activity. Risk rises sharply with combinations: MAOIs, other SSRIs/SNRIs, tramadol, triptans, MDMA, dextromethorphan, linezolid, St John's wort. Symptoms include agitation, tremor, hyperthermia, autonomic instability
  • Drug interactions via CYP1A2. Fluvoxamine is a potent CYP1A2 inhibitor and will significantly elevate levels of caffeine, theophylline, clozapine, olanzapine, ramelteon, melatonin, tizanidine, and agomelatine. The clozapine interaction is sometimes used clinically (low-dose fluvoxamine boosts clozapine levels and may reduce some metabolic side effects) but should only be done under specialist supervision
🩸

Blood markers

Sodium, baseline before starting and at 2-4 weeks if you're over 65, female, low body weight, or on a diuretic. SSRI-induced hyponatraemia usually appears in the first month and can be serious if missed.
Liver enzymes (ALT, AST), baseline. Fluvoxamine is hepatically metabolised and cleared more slowly with liver dysfunction. Recheck if symptoms suggest hepatic strain.
TSH, baseline if you have any history of thyroid issues or low mood that might actually be hypothyroid in origin. SSRIs don't directly affect thyroid function but you want to rule out an alternative explanation for symptoms before committing to long-term treatment.
ECG, baseline if you have cardiac history, are over 65, or are on other QT-prolonging medications. Fluvoxamine itself is reasonably safe cardiac-wise but worth a baseline reference.
Pregnancy test, before starting in women of reproductive age. Decisions about SSRI use in pregnancy are individualised and depend on knowing the situation.
For most healthy adults starting fluvoxamine for OCD or anxiety, baseline sodium, liver enzymes, and a basic metabolic panel is sufficient. The bloodwork that actually matters most isn't standard chemistry, it's tracking response and side effects week to week with your prescriber and being honest about what's happening.
Fluvoxamine is a prescription drug in essentially all jurisdictions.